Showing results (31-40 of 155) with videos related to

Sort By:
Pageof 16
The Journal of Dermatology|November 3, 2019
Six cases of perforating pilomatricoma: Anetodermic changes with expression of matrix metalloproteinasesDaisuke Watabe, Shiho Mori, Toshihide Akasaka, et al.
Clinical Immunology (Orlando, Fla.)|January 21, 2021
Immunological features of circulating monocyte subsets in patients with squamous cell carcinoma of the head and neckKoichi Sakakura, Hideyuki Takahashi, Sei-Ichiro Motegi, et al.
The Journal of Dermatology|January 14, 2015
Clinical and laboratory features of systemic sclerosis complicated with localized sclerodermaSayaka Toki, Sei-ichiro Motegi, Kazuya Yamada, et al.
The Journal of Dermatology|November 1, 2018
Two cases of chronic oral ulcers effectively treated with systemic corticosteroid therapy: Circumorificial plasmacytosis and traumatic ulcerative granuloma with stromal eosinophiliaYuko Kuriyama, Akira Shimizu, Sayaka Toki, et al.
The Journal of Dermatology|January 5, 2026
Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World StudyMizuki Shiba, Teppei Hagino, Akihiko Uchiyama, et al.
Experimental Dermatology|May 28, 2015
Global DNA hypomethylation and hypoxia-induced expression of the ten eleven translocation (TET) family, TET1, in scleroderma fibroblastsMai Hattori, Yoko Yokoyama, Tomoyasu Hattori, et al.
The Journal of Dermatology|February 11, 2026
Effectiveness of Anti-IL-13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48-Week Outcomes by Lebrikizumab and TralokinumabMizuki Shiba, Teppei Hagino, Akihiko Uchiyama, et al.
The Journal of Dermatology|February 16, 2026
Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch SeverityManami Yoneyama, Teppei Hagino, Akihiko Uchiyama, et al.
The Journal of Dermatology|December 12, 2018
Cutaneous adult xanthogranuloma with a small portion of BRAF<sup>V</sup> <sup>600E</sup> mutated Langerhans cell histiocytosis populations: A case report and the review of published workMai Ishikawa, Yukie Endo, Akihito Uehara, et al.
European Journal of Dermatology : EJD|May 25, 2026
Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)Yohei Takahashi, Teppei Hagino, Akihiko Uchiyama, et al.
Pageof 16